Loading stock data…
HELP
$5.15-0.16 (-3.01%)
Market ClosedLast close May 1
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cybin D/B/A Helus Pharma in the Healthcare sector is trading at $5.15. The stock is currently near its 52-week low of $4.29, remaining 20.3% below its 200-day moving average. Technical signals show neutral RSI of 46 and bearish MACD signal, explaining why HELP maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.15
Potential Upside
5%
Whystock Fair Value$5.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in pha...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$287.89M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.72%
Volume
Today's trading volume
690,684
Recent News
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk?
Earlier this month, Helus Pharma (operating as Cybin) reshaped its leadership by appointing interim CEO Eric So, expanding medical leadership with Dr. Ken Kramer as Senior Vice President of Medical Affairs, and adding renowned experts Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board. By bringing together high-profile figures in biotechnology, CNS drug development, and medical affairs, Helus Pharma is signaling an emphasis on clinically rigorous development of its...
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
Shares of some psychedelic drug companies gained Friday morning after the US Food and Drug Administr
Trump Signed a Psychedelic Drugs Order—and These 4 Stocks Surged
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness
Compass Pathways (CMPS) and other psychedelic shares were up in Monday premarket activity, after US
Cybin Insider Ups Holding By 105% During Year
Looking at Cybin Inc.'s ( NASDAQ:HELP ) insider transactions over the last year, we can see that insiders were net...